CN100515430C - Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D - Google Patents
Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D Download PDFInfo
- Publication number
- CN100515430C CN100515430C CNB2005100557478A CN200510055747A CN100515430C CN 100515430 C CN100515430 C CN 100515430C CN B2005100557478 A CNB2005100557478 A CN B2005100557478A CN 200510055747 A CN200510055747 A CN 200510055747A CN 100515430 C CN100515430 C CN 100515430C
- Authority
- CN
- China
- Prior art keywords
- calcium
- magnesium
- vitamin
- medicine preparation
- additional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 239000011575 calcium Substances 0.000 title claims abstract description 74
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 74
- 229930003316 Vitamin D Natural products 0.000 title claims abstract description 37
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 37
- 239000011710 vitamin D Substances 0.000 title claims abstract description 37
- 235000019166 vitamin D Nutrition 0.000 title claims abstract description 37
- 150000003710 vitamin D derivatives Chemical class 0.000 title claims abstract description 37
- 229940046008 vitamin d Drugs 0.000 title claims abstract description 37
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000011777 magnesium Substances 0.000 title claims abstract description 25
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 25
- 230000001502 supplementing effect Effects 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229960005069 calcium Drugs 0.000 claims description 69
- 229940091250 magnesium supplement Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 claims description 17
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 16
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 13
- 239000007968 orange flavor Substances 0.000 claims description 13
- 229940013618 stevioside Drugs 0.000 claims description 13
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 13
- 235000019202 steviosides Nutrition 0.000 claims description 13
- 239000000395 magnesium oxide Substances 0.000 claims description 12
- 235000012245 magnesium oxide Nutrition 0.000 claims description 12
- 229960000869 magnesium oxide Drugs 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 229920003081 Povidone K 30 Polymers 0.000 claims description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 8
- 229960003563 calcium carbonate Drugs 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229960002713 calcium chloride Drugs 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 229960002337 magnesium chloride Drugs 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- 108010033929 calcium caseinate Proteins 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 239000001362 calcium malate Substances 0.000 claims description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims description 2
- 229940016114 calcium malate Drugs 0.000 claims description 2
- 235000011038 calcium malates Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 2
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229960001708 magnesium carbonate Drugs 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- 239000011742 magnesium glycerophosphate Substances 0.000 claims description 2
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 2
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 2
- 239000000626 magnesium lactate Substances 0.000 claims description 2
- 235000015229 magnesium lactate Nutrition 0.000 claims description 2
- 229960004658 magnesium lactate Drugs 0.000 claims description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
- 239000004137 magnesium phosphate Substances 0.000 claims description 2
- 229960002261 magnesium phosphate Drugs 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 206010006956 Calcium deficiency Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000003076 Osteolysis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal preparation for supplementing calcium, magnesium and vitamin D, which mainly contains a calcium agent, a magnesium agent and vitamin D, wherein each 100g of the medicinal preparation for supplementing calcium, magnesium and vitamin D contains: 17-23g of calcium element, 8.5-11.5g of magnesium element and 57IU-77IU of vitamin D. The pharmaceutical preparation for supplementing calcium, magnesium and vitamin D has the advantages of good absorption and conversion effects, low cost and no side effect.
Description
Technical field
The present invention relates to a kind of medicine of replenishing the calcium, be used for the calcium complement agent of child, teenager, gestation, nursing women, climacteric women, middle-aged and elderly people etc., also be used for prevention of osteoporosis disease.
Background technology
Calcium is the mineral of needed by human, and 99% is present in skeleton and the tooth, and wherein 1% calcium is distributed in soft tissue and the extracellular fluid.Calcium has not only constituted the skeleton of human body, and to the integrity of keeping, keep cell membrane and the permeability of stress get excited transmission, the cardiac rhythm of the nerve of human body, muscle, keep solidifying of intravital acid-base balance, blood and all play irreplaceable important function, and calcium can reduce blood capillary permeability, prevent to ooze out, control inflammation and edema.
2000, Chinese Soclety of Nutrition formally revised and has passed through that " the Chinese residents diet nutrient is with reference to ingestion standard (DRI
s) ".In this standard, recommend the every day of calcium quantity delivered to be: 18-49 year 800mg; 1000mg more than 50 years old.
China's nutritional survey nineties shows that China belongs to the country that low calcium is taken in.About China resident calcium every day mean intake 500mg, many provinces are lower than 400mg, this is worth 50% of not enough physiology quantity delivered, also the standard of adult 800mg every day that stipulates in the relevant nutrient meals recommended amounts standard (RDA) far below nineteen ninety Chinese Soclety of Nutrition's revision; More be lower than the standard that some countries of west take in 1000-1200mg every day.
Human calcium's Deficiency of Intake can influence body development, and can cause multiple disease.The serious calcium deficiency of anemia of pregnant woman is then twitched, preeclampsia etc.; Person in middle and old age's calcium deficiency then can cause hypertension, arteriosclerosis and joint lumbago and skelalgia; The most general generation then be the osteoporosis syndrome of middle-aged and elderly people.The undernutrition of calcium is not only the child, also becomes the important nutrition problem of person in middle and old age colony.
The calcium that needed by human body is wanted mainly comes from food, and China is that vegetation foodstuff is the country of traditional diet structure of master, and the clothes milk product is less.People have recognized the danger that low calcium is taken at present, and not only calcium replenishes and is subjected to extensive attention in the food, and calcium preparation also begins to be used for the preventative of calcium deficiency and replenishes when being used for the treatment of.
Replenish the calcium additional can being divided at the preventative of calcium deficiency crowd of calcium, replenishes the calcium at carrying out health with the related special population of calcium deficiency relevant disease, carries out therapeutic at the disease crowd and replenish the calcium.
Yet, existing calcium preparation also comes with some shortcomings, and mainly shows: in the process of replenishing the calcium, particularly replenish the calcium and during therapeutic replenishes the calcium in health, the unconspicuous problem of effect of supplemented calcium can appear in some people, mainly is that human body is bad to the absorption and the trans-utilization effect of calcium.Vitamin D is one of important calcium-regulating hormone, and the conversion that absorbs of intestinal calcium absorption and calcium all be unable to do without vitamin D.For strengthening the absorption and the conversion of calcium, also added vitamin D in some calcium preparation at present, but, still made the absorption of calcium and transform undesirable because of vitamin D and the content and the ratio of calcium preparation in calcium preparation are unreasonable.
Summary of the invention
At present calcium preparation above shortcomings and people deficiency, the object of the present invention is to provide a kind ofly to be easy to absorb and to transform, have no adverse reaction and the medicine preparation of lower-cost additional calcium magnesium and vitamin D to calcium intake.
The medicine preparation of additional calcium magnesium provided by the invention and vitamin D mainly contains calcium preparation, magnesia mixture and vitamin D, contains in the medicine preparation of additional calcium magnesium of every 100g and vitamin D: calcium constituent 17-23g, magnesium elements 8.5-11.5g, vitamin D 57IU-77IU.
As a kind of preferred embodiment, contain calcium constituent 20g, magnesium elements 10g, vitamin D 67IU in the medicine preparation of additional calcium magnesium of every 100g and vitamin D.
In the product that contains calcium constituent that described calcium preparation can be absorbed by the body for calcium acetate, calcium carbonate, calcium caseinate, calcium chloride, calcium citrate, calcium cirate malate, calcium gluconate, calcium lactate, calcium malate, calcium hydrogen phosphate, dalcium biphosphate, calcium phosphate, calcium sulfate, calcium ascorbate, calcium glycerophosphate, biological calcium etc. one or more.
In the product that contains magnesium elements that described magnesia mixture can be absorbed by the body for magnesium oxide, magnesium carbonate, magnesium chloride, magnesium citrate, magnesium gluconate, magnesium lactate, magnesium hydrogen phosphate, magnesium phosphate, magnesium glycerophosphate etc. one or more.
Described dosage form can be prior dosage form such as granule, tablet, powder, capsule.
Described dosage form is preferably tablet, and wherein adjuvant is made up of an amount of lactose and mannitol, stevioside, orange flavor powder, 5%PVP-K30 (ketopyrrolidine), magnesium stearate.
The weight content of described lactose, stevioside, orange flavor powder the best in tablet is respectively: lactose 10-12%, stevioside 0.25-0.6%, orange flavor powder 0.5-1%.
For tablet, every weight is 1.5g, adult 2 of every days, divides and takes for 1-2 time.1 of child one day, once-a-day.
For other dosage form, the dose of every day can be taken by the calcium intake standard of above-mentioned tablet every day.
The medicine preparation of this additional calcium magnesium and vitamin D is applicable to the calcium complement agent of child, teenager, gestation, nursing women, climacteric women, middle-aged and elderly people etc. also to be used for prevention of osteoporosis disease.
The beneficial effect of the medicine preparation of additional calcium magnesium of the present invention and vitamin D is:
(1) in the medicine preparation of additional calcium magnesium of the present invention and vitamin D, carry out scientific and reasonable collocation by consumption to vitamin D and calcium carbonate, promotion calcium by vitamin D is in enteral absorption, and make vitamin D can have skeletonization and osteolysis, under physiological dose, promote skeletonization, rely on parathyroid gland parathyrine performance osteolysis when heavy dose of, indirect adjusting blood calcium is in normal range, so good to the absorption and the changing effect of calcium.
(2) magnesium is the macroelement of needed by human, is one of important component of bone and tooth.The key of replenishing the calcium is absorbing, calcium absorption is subjected to influence of various factors, the relation of calcium and magnesium is very close, magnesium deficiency then calcium absorption is bad, magnesium can promote absorbing of calcium, also with the activity of magnesium catalysis, activation plurality of enzymes, participate in many biochemical reactions relevant with bone metabolism, it is an important element that promotes calcium absorption.Do not have enough magnesium, calcium can not fully absorb.Magnesium plays an important role in absorption, content, combination and the redistribution of control calcium, the transportation of magnesium relies on calcium pump, and the metabolism of calcium relies on the adjusting of magnesium, can strengthen the indraft of calcium when hanging down magnesium, the indraft of retardance calcium during high magnesium, so the necessary balance of magnesium and calcium is also answered magnesium supplement when replenishing the calcium, prevent low magnesium high calcium.The medicine preparation of additional calcium magnesium of the present invention and vitamin D, owing to contain magnesium oxide, and the consumption of calcium and magnesium is reasonable, replenished magnesium again in the while of replenishing the calcium, can recover two kinds of ionic balances in the body, particularly with the vitamin D combined effect, promoted the absorption and the metabolism of calcium, so advantages of good calcium supplying effect.
(3) magnesium has significant protective effect to cardiovascular; therefore the medicine preparation of additional calcium magnesium of the present invention and vitamin D can obviously improve hdl level when replenishing the calcium; simultaneously remarkable triglyceride reducing, cholesterol and low-density lipoprotein white level; thereby prevent and treat the atherosclerosis of hyperlipemia and secondary thereof effectively, and then protection heart and brain organ.
(4) make tablet, be convenient to packing, store and take, add rational microcrystalline Cellulose, help disintegrate and absorb.
(5) when adopting tablet, the present invention is also selected lactose, stevioside, orange flavor powder be as correctives, and pass through the reasonably combined of three kinds of correctivess, makes this tablet features good taste, is particularly suitable for child's usefulness of replenishing the calcium.
The specific embodiment
Below in conjunction with specific embodiment the medicine preparation that the present invention replenishes calcium magnesium and vitamin D is described further.
Embodiment 1
Calcium carbonate 75g, magnesium oxide 25g, vitamin D1 00IU, microcrystalline Cellulose 15g, lactose 17.3g, mannitol 15g, stevioside 0.45g, orange flavor powder 0.75g, magnesium stearate 1.5g and 5%PVP-K30 are made 100 tablets of tablets in right amount.
Embodiment 2
Calcium chloride 95g, magnesium oxide 21.1g, vitamin D1 15IU, microcrystalline Cellulose 10g, lactose 10.2g, mannitol 11g, stevioside 0.45g, orange flavor powder 0.75g, magnesium stearate 1.5g and 5%PVP-K30 are made 100 tablets of tablets in right amount.
Embodiment 3
Calcium chloride 71.4g, calcium gluconate 16.1g, magnesium oxide 28.6g, vitamin D 85IU, microcrystalline Cellulose 10g, lactose 10.2g, mannitol 11g, stevioside 0.45g, orange flavor powder 0.75g, magnesium stearate 1.5g and 5%PVP-K30 are made 100 tablets of tablets in right amount.
Embodiment 4
With dalcium biphosphate 40g, calcium carbonate 48.5g, magnesium chloride 30g, magnesium carbonate 30, magnesium stearate 1.5g, porphyrize sieves, and adding vitamin D1 00IU mix homogeneously is encapsulated.
Embodiment 5
With calcium carbonate 75g, magnesium oxide 25g, vitamin D 90IU, microcrystalline Cellulose 15g, lactose 17g, mannitol 14.1g, stevioside 0.9g, an amount of, the magnesium stearate 1.5g film-making of orange flavor powder 0.75g, 5%PVP-K30, make 100 altogether
Embodiment 6
With calcium carbonate 75g, magnesium oxide 25g, vitamin D1 10IU, microcrystalline Cellulose 15g, lactose 15g, mannitol 15g, stevioside 1g, an amount of, the magnesium stearate 1.5g of orange flavor powder 2.5g, 5%PVP-K30, make 100 tablets of tablets altogether
Embodiment 7
With calcium carbonate 75g, magnesium oxide 25g, vitamin D1 00IU, microcrystalline Cellulose 15g, lactose 16g, mannitol 15g, stevioside 1g, an amount of, the magnesium stearate 1.5g of orange flavor powder 1.5g, 5%PVP-K30, make 100 tablets of tablets.
Claims (6)
1, the medicine preparation of a kind of additional calcium magnesium and vitamin D is characterized in that, contains calcium constituent 20g, magnesium elements 10g, vitamin D 67IU in this medicine preparation of every 100g.
2, the medicine preparation of additional calcium magnesium as claimed in claim 1 and vitamin D, it is characterized in that: described calcium preparation is one or more in calcium acetate, calcium carbonate, calcium caseinate, calcium chloride, calcium citrate, calcium cirate malate, calcium gluconate, calcium lactate, calcium malate, calcium hydrogen phosphate, dalcium biphosphate, calcium phosphate, calcium sulfate, calcium ascorbate, calcium glycerophosphate, the biological calcium.
3, the medicine preparation of additional calcium magnesium as claimed in claim 1 and vitamin D, it is characterized in that: described magnesia mixture is one or more in magnesium oxide, magnesium carbonate, magnesium chloride, magnesium citrate, magnesium gluconate, magnesium lactate, magnesium hydrogen phosphate, magnesium phosphate, the magnesium glycerophosphate.
4, the medicine preparation of additional calcium magnesium as claimed in claim 1 and vitamin D is characterized in that: said preparation is tablet or granule, capsule.
5, the medicine preparation of additional calcium magnesium as claimed in claim 4 and vitamin D is characterized in that: be tablet, wherein adjuvant is made up of lactose, mannitol, stevioside, orange flavor powder, 5%PVP-K30, magnesium stearate.
6, the medicine preparation of additional calcium magnesium as claimed in claim 5 and vitamin D, it is characterized in that described lactose, stevioside, the weight content of orange flavor powder in tablet are respectively: lactose 10-12%, stevioside 0.25-0.6%, orange flavor powder 0.5-1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100557478A CN100515430C (en) | 2005-03-21 | 2005-03-21 | Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100557478A CN100515430C (en) | 2005-03-21 | 2005-03-21 | Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686182A CN1686182A (en) | 2005-10-26 |
| CN100515430C true CN100515430C (en) | 2009-07-22 |
Family
ID=35304224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100557478A Expired - Fee Related CN100515430C (en) | 2005-03-21 | 2005-03-21 | Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100515430C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014523921A (en) * | 2011-07-27 | 2014-09-18 | シノベダ カナダ，インク． | Formulation containing highly soluble ingredients and vitamins for prevention and recovery of osteoporosis |
| CN105125579A (en) * | 2015-09-10 | 2015-12-09 | 重庆布尔动物药业有限公司 | Calcium, magnesium and vitamin injection |
| CN105963318B (en) * | 2016-05-03 | 2018-12-14 | 宣城柏维力生物工程有限公司 | A kind of calcium and magnesium dimension D piece and preparation method thereof |
| CN106619705A (en) * | 2016-12-02 | 2017-05-10 | 芜湖市诺康生物科技有限公司 | Soft capsules containing calcium, magnesium and vitamin D and preparation method of soft capsules |
| CN106913856A (en) * | 2017-04-07 | 2017-07-04 | 南通市第人民医院 | A kind of animal specific calcium tablet and preparation method thereof |
| CN114431479A (en) * | 2020-11-05 | 2022-05-06 | 浙江创新生物有限公司 | Calcium-magnesium vitamin D chewable tablet and preparation method thereof |
-
2005
- 2005-03-21 CN CNB2005100557478A patent/CN100515430C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 钙剂的分类及临床选择. 符玫等.现代诊断，第12卷第6期. 2001 |
| 钙剂的分类及临床选择. 符玫等.现代诊断，第12卷第6期. 2001 * |
| 食品添加剂中镁的化合物. 陈勉哉.中国食品添加剂，第1期. 1995 |
| 食品添加剂中镁的化合物. 陈勉哉.中国食品添加剂，第1期. 1995 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686182A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106072573A (en) | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible | |
| WO2011060585A1 (en) | Chewable tablets including essences of five-colour fruits and vegetables and preparative methods thereof | |
| CN100403932C (en) | Nutrition powder for increasing memory | |
| CN104366475B (en) | A kind of enhancement mode health products | |
| CN101683477A (en) | Composition for fat-reducing | |
| CN112189711A (en) | Milk powder for assisting in reducing hypertension, hyperglycemia and hyperlipidemia of middle-aged and old people | |
| CN105412406A (en) | Traditional Chinese medicine composition for reducing blood viscosity and preparing method thereof | |
| CN101040710A (en) | Health-care nutritious medicinal granules which can be took orally for controlling the incretion for women and can also be used on the skin for beauty | |
| KR20020006114A (en) | Manufacturing Method of Absorptive Zinc-Oligopeptide in The Human Body | |
| EP1198994B1 (en) | Health food products | |
| CN100515430C (en) | Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| KR100455222B1 (en) | A diet ginseng products and the preparing method thereof | |
| CN104001157B (en) | Compound preparation of a kind of protect against osteoporosis and preparation method thereof | |
| CN110214942A (en) | A kind of hyperthyroidism tailored version Nutrition formula and preparation method thereof | |
| CN104106828A (en) | Solid beverage for reducing blood glucose | |
| CN100515429C (en) | Calcium and magnesium supplementing medicinal preparation | |
| CN105533721A (en) | Key fruit oil oral emulsion and preparation method thereof | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
| CN108851037A (en) | A kind of preparation method and its usage of nephrotic syndrome wholefood | |
| JPH09238615A (en) | Health nutritive food | |
| CN101019846A (en) | Prepn of capsule containing pyruvic acid and its salt | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| CN101204400A (en) | Prescripton and preparing method of colla corii asini line products | |
| CN107319296A (en) | A kind of digestible Semen setariae health care meal and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUNAN THEIL PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENG GANG Effective date: 20080404 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080404 Address after: Liuyang City, Hunan Province, North Li Qiao bridge, Hunan, Changsha mailbox, code: 410011 Applicant after: Hunan Taier Pharmaceutical Company Limited Address before: Hunan province Changsha Shinan District South Road No. 179 post encoding: 410000 Applicant before: Cheng Gang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal preparation for supplementing calcium, magnesium and vitamin D Effective date of registration: 20150212 Granted publication date: 20090722 Pledgee: Bank of Beijing Limited by Share Ltd Changsha branch Pledgor: Hunan Taier Pharmaceutical Company Limited Registration number: 2015430000004 |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20161107 Granted publication date: 20090722 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20191107 Granted publication date: 20090722 |
|
| PD01 | Discharge of preservation of patent | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090722 Termination date: 20210321 |